Condition

Heart Failure With Mid Range Ejection Fraction

ClinicalTrials.gov condition label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 13 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials13
Recruiting4
Common interventions20
Lead sponsors shown13
Advertisement

Clinical trials

13 shown
A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart DiseaseNCT07214376 · 2026-08-21
RECRUITING
Demographic, Clinical, Biological, Treatment Characteristics and Cardiovascular Events of Patients With Heart Failure in Vietnam: a Multicenter Prospective Observational StudyNCT06516562 · 2023-08-01
RECRUITING
Assessment of CCM in HF With Higher Ejection FractionNCT05064709 · 2022-02-03
RECRUITING
Biomechanical Precision Medicine Registry for Patients With and Without Heart FailureNCT03480633 · 2016-04-07
RECRUITING
A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart FailureNCT05824923 · 2023-08-14
ACTIVE_NOT_RECRUITING
Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection FractionNCT05600387 · 2022-11-05
UNKNOWN
Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid CardiomyopathyNCT05795400 · 2022-06-01
COMPLETED
The Effect of Oxygen Supplementation in Training in Heart Failure Patients on Aerobic Performance and Quality of LifeNCT06481657 · 2022-02-10
COMPLETED
Extended IASD Investigation: REDUCE LAP-HF IVNCT04632160 · 2021-12-01
WITHDRAWN
Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III StudyNCT04600921 · 2021-06-24
TERMINATED
CMR T1 Mapping for Diagnosis of Cardiac AmyloidosisNCT04862273 · 2021-04-01
COMPLETED
Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)NCT05204238 · 2020-09-01
UNKNOWN
Outcome of Discharged HFmrEF PatientsNCT05240118 · 2015-01-01
COMPLETED

Common interventions

Trial status mix

COMPLETED4
RECRUITING4
UNKNOWN2
ACTIVE_NOT_RECRUITING1
TERMINATED1
WITHDRAWN1

Phase mix

NA5
PHASE32
PHASE41
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.